#South Korea #Seoul #Eli Lilly #Hanmi #sonefpeglutide

Hanmi Pharm and Eli Lilly: A Strategic Licensing Agreement

Hanmi Pharm. Co., Ltd., a leading biopharmaceutical company based in South Korea, has made headlines with its recent licensing agreement with Eli Lilly and Company. This significant collaboration focuses on the development, manufacturing, and commercialization of sonefpeglutide, an innovative biologic drug candidate utilizing Hanmi's proprietary long-acting platform technology known as LAPSCOVERY™.

The Potential of Sonefpeglutide

Sonefpeglutide, a novel analog of the glucagon-like peptide (GLP-2), has shown Promise in enhancing intestinal health and function. Through a series of non-clinical studies, Hanmi has demonstrated the drug's ability to support intestinal growth, reduce inflammation, and offer protective and regenerative effects on the intestinal mucosa. These findings have been acknowledged in presentations at major scientific conferences, underlining the drug's therapeutic potential across a variety of indications.

Continuing Clinical Trials

Currently, Hanmi is conducting a global Phase 2 clinical trial for short bowel syndrome (SBS), where sonefpeglutide is being evaluated for its efficacy. Hanmi plans to maintain its commitment to the completion of this trial, ensuring that the data gathered is both robust and reliable. Eli Lilly, as part of the agreement, will have the opportunity to develop additional clinical trials based on the existing nonclinical and clinical data collected during Hanmi's research efforts.

Exclusive Rights and Financial Aspects

Under the terms of the agreement, Lilly gains exclusive rights to develop, manufacture, and commercialize sonefpeglutide on a global scale, with the exception of Korea where Hanmi retains its marketing rights. Hanmi will receive an initial payment of $75 million and stands to earn as much as $1.185 billion in potential milestone payments related to clinical development, regulatory approvals, and commercialization success. Furthermore, Hanmi will be entitled to royalties following the product's commercial launch.

Statements from Leadership

Juhyun Lim, Vice Chairman of Hanmi, expressed enthusiasm about the partnership, stating, "It is highly meaningful that Lilly—one of the most globally recognized innovators—has identified the development potential for sonefpeglutide." Lim emphasized Hanmi's commitment to innovation in drug development, aligned with their mission of 'Respect for People and Value Creation.'

About Hanmi Pharm

Hanmi Pharm is committed to addressing high unmet medical needs through its focus on research and development in areas including obesity, oncology, and rare diseases. By utilizing advanced proprietary technologies, such as long-acting biologics and bispecific antibodies, Hanmi aims to foster innovative therapies that can make a significant impact on public health. The company highlights collaboration through open innovation, having established numerous global partnerships to enhance its R&D capabilities.

For more information about Hanmi Pharm, visit their official website at www.hanmipharm.com.